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Anorexia is possibly one of the most important causes of malnutrition in uremic patients. The cause of this abnormality is still unknown.
Considering that: (a) NPY is one of the most important stimulants of food intake; (b) eating is a central nervous system regulated process and (c)
NPY is expressed in hypothalamus, we hypothesized that the decrease of NPY gene expression in the hypothalamus could be an important factor
contributing to anorexia associated with uremic state. In contrast to the prediction, the results presented in this paper indicate that the NPY gene
expression in the hypothalamus of chronic renal failure (CRF) rats was significantly higher than in the hypothalamus of control (pair-fed) rats.
Moreover, we found that serum NPY concentration in CRF rats was higher than in control (pair-fed) animals. The increase of plasma NPY
concentration in CRF rats may be due to the greater synthesis of the neuropeptide in liver, since higher level of NPY mRNAwas found in liver of
CRF rats. The results obtained revealed that experimental chronic renal failure is associated with the increase of NPY gene expression in
hypothalamus and liver of rats.
© 2006 Elsevier B.V. All rights reserved.Keywords: NPY; Hypothalamus; Liver; Chronic renal failure1. Introduction
Neuropeptide Y (NPY), a 36 amino acid peptide from
pancreatic polypeptide family, is one of the most abundantly
expressed peptides in the nervous system [1]. Due to five
different NPY receptors (named as Y1 to Y5), expressed in
many tissues, this neuropeptide seems to be involved in the
regulation of variety of biological functions [1,2]. Moreover, it
has been suggested that NPY is associated with some diseases,
including obesity, hypertension, dementia and epilepsy [1]. One
major function of NPY is a regulation of appetite and body
weight homeostasis [1,2]. These actions of NPY appear to be
mediated at hypothalamic sites by Y1 and Y5 NPY receptors
[2]. NPY appears to stimulate not only food intake per se, but
specifically the preference for carbohydrates [2], which in turn⁎ Corresponding author. Fax: +48 58 349 1465.
E-mail address: juls@amg.gda.pl (J. Swierczynski).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.08.008increase NPY mRNA level in arcuate nuclei (ARC), a prime
controlling center of food intake [2].
Poor nutritional status has been demonstrated in some
uremic patients [3,4], which has been related to high morbidity
and mortality both in hemodialysis [5] and peritoneal dialysis
patients [6]. Moreover, it has been reported that food
consumption declines as renal function is deteriorating [7].
Several factors can contribute to a poor nutritional status [8].
Anorexia is possibly one of the most important causes of
malnutrition in the uremic state [9]. Although the cause of
uremic state associated anorexia is unknown, several factors can
contribute to this pathological state [10]. Considering that NPY
is one of the most important stimulants of food intake, one can
suppose that this hormone is contributing to malnutrition
observed in uremic patients [2,11]. Aguilera et al. [12] found
normal plasma NPY concentration in 66%, lower in 22% and
higher in 12% of peritoneal dialysis patients. Moreover, they
found that peritoneal dialysis patients with anorexia display
lower NPY concentration than those without anorexia [12].
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usually with an elevated plasma NPY concentration [13–20].
These discrepancy could be associated to different stage of renal
failure and/or to the criteria used to define anorexia [21].
Recently, it has been concluded that anorexia in CRF patients
was not due to deficient plasma NPY concentration [22].
However, regarding that (a) eating is a central nervous system-
regulated process, and (b) NPY gene is expressed in the
hypothalamus [1], it cannot be excluded that uremia related
anorexia may result from the diminished hypothalamic NPY
gene expression. The main hypothesis of this study is that the
inhibition of NPY gene expression in hypothalamus of CRF rats
may occur and that this phenomenon could play an important
role in the pathogenesis of uremia-associated anorexia. To
check this hypothesis in the present study we examine the NPY
mRNA level in the hypothalamus of CRF failure rats and
compare to the NPY mRNA level in the hypothalamus of sham-
operated pair-fed rats. Additionally, to answer the question
whether changes in NPY gene expression are limited to the
hypothalamus or occur in other tissues of CRF rats, we analyzed
NPY mRNA level in liver of CRF and the pair-fed animals.
2. Materials and methods
2.1. Animals
Male Wistar rats (10 week old, weight approximately 250 g at the beginning
of the study) were used in all experiments. Animals were kept in individual
cages with free access to water, and controlled lighting schedule (illuminated
from 7 am to 7 pm). Experimental chronic renal failure (CRF) was induced by
two-stage (5/6) subtotal nephrectomy as described previously [23]. Average
daily food intake was measured by the difference in weight between the amount
of food provided and the amount remaining over a 1 day period. Pair-fed (sham-
operated) rats received the amount of food (commercial diet containing 23% of
protein, composition of which has been described previously [24])
corresponding to what had been consumed by the matched chronic renal failure
(CRF) animals. The non-fasted overnight rats were killed (between 8 am to
10 am) 6 weeks after induction of renal failure. Blood samples were collected
from abdominal aorta and determination of blood pH, pCO2, urea, creatinine,
albumin, transferrin, triacylglycerols and cholesterol (total, HDL-cholesterol,
LDL-cholesterol) was performed. Hypothalamic portion of the brain and liver
specimens were dissected and rapidly frozen in liquid nitrogen. The tissues were
stored at −80 °C until analysis. All animal procedures were conducted in
agreement with our institutional guidelines for the care and use of laboratory
animals.
2.2. RNA isolation
Total cellular RNAwas extracted from frozen hypothalamus and liver by the
guanidinium isothiocyanate-phenol/chloroform method [25] and finally dis-
solved in dimethyl pyrocarbonate-treated water. The RNA concentration was
determined from the absorbance at 260 nm and all samples had the 260/280 nm
absorbance ratios about 2.0.
2.3. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
First strand cDNA was synthesised from 1 μg of total RNA (RevertAid™
First Strand cDNA Synthesis Kit—Fermentas). Prior to amplification of cDNA,
each RNA sample was treated with RNase-free DNase I (Fermentas) at 37 °C for
30 min. The cDNAwas used as a template in Multiplex PCR reaction with the
housekeeping β-actin gene, as an internal control. The cDNA samples are
amplified for 30 cycles (94 °C for 45 s, 60 °C for 45 s, 72 °C for 45 s) at a final
volume of 20 μl containing 1× PCR buffer, 3.5 mMMgCl2, 0.5 mM dNTPMix,0.5 mM of sense and antisense primers and 0.5 U Taq DNA Polymerase
(Fermentas). Specific sense and antisense primers used for the preparations of
respective cDNA was: NPY 5′-TAGGTAACAAACGAATGGGG-3′ and 5′-
AGGATGAGSTGAGAGTGGG-3′ [26]; β-actin 5′-GAAATCGTGCGTGA-
CATTAAG-3′ and 5′-GCTAGAAGCATTTGCGGTGGA-3 [27]. The RT-PCR
products were analysed by 1.5% agarose gel electrophoresis. Band intensities
were compared by imaging of ethidium bromide staining and quantified using
Sigma Scan software program (Jandel Scientific Co.). Results are expressed in
arbitrary units.
2.4. Determination of mRNA levels by real-time RT-PCR
Hypothalamus NPY mRNA expression was quantified by real-time RT-PCR
using iCycler iQ Real Time Detection System (Bio-Rad, Hercules, USA).
Primers were designed with Sequence Analysis software package (Informagen,
Newington, USA) from gene sequences obtained from Ensembl Genome
Browser (www.ensembl.org). The following oligonucleotide primer pairs were
used: TCATCACCAGACAGAGATATGG (sense) and CCATCACCACATG-
GAAGG (antisense) for NPY; CTCATCAAGACCATTGTCACC (sense) and
AGGTCTCGCAGGTTCTCC (antisense) for β-actin. Real-time PCR amplifi-
cations were performed in a 25 μl volume using iQ SYBRGreen Supermix (Bio-
Rad), as previously described [28]. Each reaction contained 2 μl of cDNA and
0.3 μM of each primer. Samples were incubated for an initial denaturation and
polymerase activation at 95 °C for 5 min, followed by 40 PCR cycles each
consisting of 95 °C for 20 s, 55 °C for 20 s, and 72 °C for 40 s. Controls without
RT and with no template cDNAwere performed with each assay and all samples
were run in triplicate. To compensate for variations in input RNA amounts, and
efficiency of reverse transcription, β-Actin mRNA was quantified and results
were normalized to these values. Relative quantities of transcript were calculated
using the 2-ΔΔCt formula [29]. The results are expressed in arbitrary units, with
one unit being the mean mRNA level determined in the control group.
Amplification of specific transcripts was further confirmed by obtaining melting
curve profiles and subjecting the amplification products to agarose gel
electrophoresis.
2.5. Plasma NPY concentration
Plasma NPY concentration was estimated by radioimmunoassay method
using kit from Penisula Laboratories, USA after extraction of this hormone by
Sep-Pac C18 Cartridges (Waters Associates, Milfold Massachusetts, USA).
2.6. Statistical analysis
The statistical significance of differences in hypothalamic and liver NPY
mRNA level, serum NPY concentration and serum creatinine, urea and serum
lipids concentrations were analyzed using ANOVA followed by Student's t test
using the systat software (Systat). The data are expressed as mean±SD.
Significance was defined by p<0.05.
3. Results
Table 1 displays some parameters characteristic for CRF
found in nephrectomized rats when compared to control (pair-
fed, sham-operated) animals. Serum concentrations of both urea
and creatinine increased approximately 3- and 4-fold respec-
tively in CRF rats as compared to pair-fed animals. Simulta-
neously, the induction of CRF resulted in 3-fold increase in
serum triacylglycerol concentration as compared to pair-fed
rats. Moreover, we observed approximately 2- to 3-fold increase
of serum total cholesterol concentration, HDL-cholesterol
concentration and LDL-cholesterol concentration. At the end
of experiment, body weights were lower in CRF rats as
compared to the pair-fed animals. This was due to smaller body
weight gain, since at the start point, all tested animals had
Fig. 2. NPY mRNA level in hypothalamus of chronic renal failure rats (CRF)
and pair-fed rats. (A), representative agarose gel electrophoresis of products
corresponding to NPY and β-actin, amplified by Multiplex PCR method. The
individual lanes represent individual rats. The measurements were in the linear
range of the assay. (B), NPY mRNA level (mean±SD) in each group (n=10)
was quantified as described in Materials and methods. The cDNA amplified
from β-actin mRNA was to normalize corresponding NPY results. Data are
expressed in arbitrary units (*p<0.01).
Table 1








Creatinine (mg/dl±SD) 2.4±0.9 0.6±0.1 p<0.01
Urea (mg/dl±SD) 295.9±71.1 84.0±4.5 p<0.01
pH 7.40±0.08 7.39±0.04 n.s.
Bicarbonate (mmol/l±SD) 27.2±2.7 26.4±1.8 n.s.
Glucose (mg/dl±SD) 151.4±16.8 163.8±14.4 n.s.
Albumin (g/l±SD) 33±4 38±2 p<0.05
Transferrin (g/l±SD) 0.8±0.2 1.1±0.1 p<0.05
Triacylglycerol (mg/dl±SD) 229.6±97.1 74.2±26.9 p<0.01
Total cholesterol (mg/dl±SD) 176.3±20.5 69.8±20.5 p<0.01
HDL-cholesterol (mg/dl±SD) 79.6±22.5 35.3±11.2 p<0.01
LDL-cholesterol (mg/dl±SD) 50.7±14.2 19.8±5.5 p<0.01
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in both groups. Considering that body weight was significantly
lower in CRF rats than in pair-fed animals (365±40 g versus
426±23 g; p<0.01), one can conclude that other factors than
the amount of food consumption contribute to lower body
weight gain in CRF animals. Blood bicarbonate concentration
and pH was not different in CRF rats and control (pair-fed)
animals (Table 1). The above data indicate that CRF rats were
uremic but not acidotic when sacrificed. Serum concentrations
of some nutritional markers such as albumin and transferrin
were slightly lower in CRF rats as compared to control (pair-
fed) animals (Table 1). Serum glucose concentration was not
different in CRF rats and control (pair-fed) animals (Table 1).
Most of the abnormalities found in our experimental model of
CRF resemble these observed in chronic renal failure patients.
The results presented in Fig. 1 indicate that serum NPY
concentration was markedly elevated in CRF rats. In this respect
the results obtained with experimental model of CRF resemble
that observed in patients with chronic renal failure [13–20].
Fig. 2A (top panel) shows a representative experiment of
NPY mRNA abundance in the hypothalamus of the pair-fed
and CRF rats. NPY mRNA level was significantly higher in the
hypothalamus of CRF rats as compared to NPY mRNA level in
the hypothalamus of pair-fed animals. β-Actin mRNA (used asFig. 1. Serum neuropeptide Y (NPY) concentration in chronic renal failure rats
(CRF) and pair-fed rats. Data are presented as mean±SD (n=10) *p<0.05.an internal control) was expressed at relatively high, essentially
similar level in the hypothalamus of pair-fed and CRF rats (Fig.
2A). Fig. 2B (bottom panel) provides a semiquantitative
analysis of the data determined from densitometric scan
(obtained from 10 animals used in experiments for each
treatment). Although the results displayed in Fig. 2B represent
relative estimates, they show that hypothalamic NPY mRNA
level was higher in CRF rats than in pair fed animals (Fig. 2B).
To confirm the results presented above, we used real-time RT-
PCR which is considered as more quantitative (and sensitive)
method to quantify the steady state NPY mRNA level in the
hypothalamus of pair-fed and CRF rats. Application of this
method provides essentially similar results as conventional RT-
PCR (not shown).
To answer the questions: (a) whether the stimulatory effect of
CRF on NPY gene expression is limited to the hypothalamus or
is observed in other tissues? and (b) what is the cause of the
increase in serum NPY concentration? We analyzed NPY
mRNA level in liver of CRF and the pair-fed rats. The liver was
chosen because this organ makes a major contribution to
circulating NPY concentration [30]. Fig. 3A (top panel) shows a
representative experiment of NPY mRNA abundance in the
liver of pair-fed and CRF rats. NPY mRNA level was
significantly higher in the liver of CRF rats than in pair-fed
animals. β-Actin mRNA abundance was essentially similar in
the liver of pair-fed and CRF rats (Fig. 3A). Fig. 3B (bottom
panel) provides a semiquantitative analysis of the data
determined from densitometric scan (obtained from 10 animals
used in experiments for each treatment). The results displayed
Fig. 3. NPYmRNA level in liver of chronic renal failure rats (CRF) and pair-fed
rats. (A), representative agarose gel electrophoresis of products corresponding to
NPY and β-actin, amplified by Multiplex PCR method. The individual lanes
represent individual rats. The measurements were in the linear range of the
assay. (B), NPY mRNA level (mean±SD) in each group (n=10) was quantified
as described in Materials and methods. The cDNA amplified from β-actin
mRNA was to normalize corresponding NPY results. Data are expressed in
arbitrary units (*p<0.01).
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rats than in pair fed animals.
4. Discussion
Anorexia is likely an important factor contributing to
malnutrition observed in chronic renal failure [9]. The
pathogenesis of anorexia in uremic patients is multifactorial,
including interactions among cytokines, neuropeptides and
uremic toxins [21,31]. Since hypothalamus plays essential role
in the regulation of food intake, it is likely that CRF associated
anorexia is caused by defective hypothalamic regulation of
appetite. We hypothesized that chronic renal failure associated
anorexia may result from hypothalamic dysfunction, especially
from diminished NPY gene expression in hypothalamus, despite
of normal [12], lower [12] or elevated plasma concentration of
this neuropeptide [12–20] in uremic patients. (The apparent
discordance between plasmaNPY concentration in CRF patients
reported previously could be associated to different stage of
renal failure and/or the criteria used to define anorexia). In
contrast to the prediction, the results presented in this paper
indicate for the first time that the NPY gene expression in the
hypothalamus of CRF rats is significantly higher than in the
hypothalamus of the pair-fed rats. Higher NPY mRNA level in
the hypothalamus of CRF rats is unlikely to be due to assay
problem, since it was confirmed by two methods (RT-PCR and
real time PCR). Moreover, we found that serum NPYconcentration in CRF rats was much higher than in the pair-
fed animals. The increase in serum NPY concentration in CRF
rats may be a result of the increased production and/or decreased
renal excretion and/or degradation. Since higher NPY mRNA
level was found in liver of CRF rats than in pair-fed animals (Fig.
3), it is very likely that higher synthesis in liver (and possibly in
other tissues) is contributing to elevated serum NPY concentra-
tion. Several investigators reported that circulating NPY
concentration was significantly increased in CRF patients [13–
20]. Therefore, the effect of chronic renal failure on serum NPY
concentration in CRF patients and CRF rats is essentially similar.
Higher serum NPY concentration, high plasma urea, creatine
and some lipids concentration (Table 1), as well as less food
intake by uremic rats suggest that the experimental model of
CRF mimics human disease. Thus, one can suppose that in
hypothalamus (and possibly in other tissues) of CRF patients,
similarly as in hypothalamus and in liver of CRF rats, higher
NPY gene expression is taking place. Assuming that higher
NPY mRNA level is strictly associated with the higher peptide
level in the hypothalamus, one can suppose that anorexia
associated with CRF is not due to insufficient NPYproduction in
hypothalamus. Measuring serumNPY concentration, Lim group
[22] suggested recently that in CRF patients, anorexia was not
due to deficient plasma NPY. Thus our findings are consistent
with, and extend, the studies of Lim group [22], who did not
examine NPY gene expression in hypothalamus.
The mechanism(s) by which CRF causes the increase of
NPY gene expression in the hypothalamus and liver is uncertain
and requires further investigation. Several potential mechan-
isms can be invoked to explain CRF-related increase of NPY
mRNA level in the hypothalamus and liver. In rodents, food
restriction for 2 weeks, or food deprivation for 4 days, does
increase NPY gene expression in the central nervous system
[32]. Since pair-fed rats did eat the same amount of food as CRF
rats and displayed lower level of NPY mRNA than CRF
animals, the amount of food intake cannot explain the
differences in NPY gene expression in pair-fed and CRF rats.
This work has some important limitation. We have not
analyzed some factors frequently associated with uremia,
including proinflammatory cytokine [33–35], sympathetic
overactivity [36], hyperinsulinemia and hyperleptinemia (21)
which may influence the NPY gene expression in hypothal-
amus and liver. Despite the limitations, this work clearly
indicated that experimental CRF is associated with increased
NPY gene expression in hypothalamus and liver. The possible
mechanism(s) by which CRF may cause the increase of NPY
gene expression in the hypothalamus and liver is discussed
below.
Korner et al. [37], showed increased level of NPY gene
expression in the presence of high insulin concentration in fed
and fasted obese rats. However, insulin administration to central
nervous system reduces NPY gene expression in the arcuate
nucleus of food-deprived lean (Fa/Fa) Zucker rats [38]. There
are also conflicting results on plasma insulin concentration in
CRF rats. Some authors reported that uremic rats displayed
hypoinsulinemia [39,40], while others indicate that uremic rats
had increased plasma insulin concentration [41,42]. Thus, the
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concentration in CRF rats and on the effect of insulin on NPY
gene expression in hypothalamus does not allow to make a clear
conclusion about the role of insulin in the regulation of NPY
gene expression in the hypothalamus of CRF rats.
It has been shown that leptin, the adipocyte-derived hormone,
which seems to play an important role in the regulation of
appetite and energy balance, down-regulates the NPY gene
expression in the hypothalamus [2]. Recent studies suggest that
leptin inhibits NPY gene transcription in the hypothalamus
through STAT3 and SOCS3 [43]. Thus, leptin in healthy subjects
is engaged in negative feedback control of energy balance.
Moreover, the ARC neurons expressing NPY are important
target of leptin actions. One can suppose that leptin can be an
important factor regulating NPY gene expression in the
hypothalamus of CRF rats. It is believed that after secretion by
adipocytes, leptin is transported to the ARC via the general
circulation, acts on leptin receptors located in the ARC and in
this way plays a critical role in inhibiting food intake.
Hormones other than insulin and leptin might be also
involved in the regulation of hypothalamic NPY gene expres-
sion. For instance elevation of serum corticosterone in CRF [22]
may affect transcriptional control of NPY gene expression [44].
Finally, the question arises why the increase of NPY gene
expression in hypothalamus of CRF rats did not prevent the
decrease in food intake of these rats. One possible explanation is
that uremic toxins may somehow modify the sensitivity of NPY
receptors, consequently modulating the effect of NPY on food
consumption.
During preparation of this manuscript, an elegant paper
appeared, which suggests that elevated plasma leptin concen-
tration may be an important cause of CRF associated anorexia
via signaling through the central melanocortin system [45].
Thus, leptin may play an important role in the pathogenesis of
uremia associated anorexia by a mechanism which is indepen-
dent of the NPY regulation of appetite. This conclusion cor-
roborates with our results.
In conclusion, the data presented in this paper indicate for the
first time that NPY mRNA abundance in the hypothalamus of
CRF rats was significantly higher than in the hypothalamus of
sham operated, pair-fed animals. Moreover, our data indicate
that the effect of CRF on NPY mRNA level is not limited to the
hypothalamus but was also observed in liver. The increase in
NPY mRNA abundance in the liver may contribute to the
increase in NPY concentration in serum of CRF animals.
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